HEALTH OF WOMAN. 2016.3(109):133–137; doi 10.15574/HW.2016.109.133 
 

The role of genetic counseling in identifying benign and malignant diseases of the female reproductive system 
 

Paliychuk O. V.

Institute of experimental pathology, Oncology and radiobiology named. R. E. Kavetsky NAS of Ukraine, Kiev,

MI «Cherkasy regional Oncology center» CHRR,

Medical center of LLC «Andromeda-plus», Cherkassy 
 

Objective: introducing the questionnaire method to identify families with aggregation of tumor pathology in the population of Cherkassy region (in patients with benign and malignant diseases of the female reproductive system (OZHRS) with a history of cancer family history), an in-depth clinical examination of women of those families, and bringing the feasibility of health -genetic counseling for the diagnosis of tumor pathology and the formation of high-risk groups of precancer and cancer OZHRS.

Materials and methods. Medical and genetic counseling 1103 (100%) patients and the introduction of their questionnaire method during the reception at the gynecologist-oncologist 343 (31.1% 0 of patients with cancer of the female reproductive system were conducted (ROZHRS) and a gynecologist – 760 ( 86.9%) in healthy women who applied for the purpose of baseline medical examination, to identify families with aggregation of tumor pathology.

Results. Analysis of clinical and genealogical data for women from such families found that the association of cancer in these families corresponds to a cancer family syndrome (Lynch II syndrome) or family cancer. A comprehensive clinical examination of probands revealed malignant and benign pathology of breast, cervical and endometrial, ovarian and digestive tract.

Conclusion. The results are the testimony of the effectiveness of the introduction of profiles, questionnaires in medical practice for clinical and genealogical analysis and evaluation of family onkoanamneza to identify a group of inherited risk ROZHRS, as well as for the timely diagnosis of precancerous and tumor pathology processes in family members s aggregation of malignant tumors.

Key words: cancer of the female reproductive system, a hereditary cancer syndrome, a genetic screening, questionnaire method, pedigrees.

REFERENCES

1. Osinskiy SP, Gluzman DF, Kliff J et al. 2007. Molecular diagnostics of tumors. Kiev:246 (In Russian).

2. Imianitov EN, Hanson KP. Molecular oncology: clinical aspects. Saint-Petersburg. Publishing House SPbMAPO. 2007:211 (In Russian).

3. Zueva EV. Clinical role of immune phenotyping of serous ovarian adenocarcinoma. Abstract of PhD thesis for medical sciences: speciality 14.01.12 – oncology. Moscow. 2010:23 (In Russian).

4. Chekhun VF. 2010. Modern state and perspectives of fundamental research in experimental and clinical oncology. Oncologiya (Oncology). 12(3):219-223 (In Ukrainian).

5. Domchek SM, Friebel TM, Singer ChF et al. 2010. http://jama.jamanetwork.com/article.aspx?articleid=186510 Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality FREE. JAMA. 304(9):967-975. http://dx.doi.org/10.1001/jama.2010.1237; PMid:20810374 PMCid:PMC2948529

6. Groep P, Wall E, Diest PJ. 2011. Pathology of hereditary breast cancer. Cell Oncol (Dordr). 34(2):71-88.

7. Antoniou AC, Gayther SA, Stratton JF et al. 2000. Risk models for familial ovarian and breast cancer. Genet. Epidemiol. 18:173-190. http://dx.doi.org/10.1002/(SICI)1098-2272(200002)18:2<173::AID-GEPI6>3.0.CO;2-R; http://dx.doi.org/10.1002/(SICI)1098-2272(200002)18:2<173::AID-GEPI6>3.3.CO;2-I

8. U.S. Preventive Services Task Force. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Clinical Summary of USPSTF Recommendation. AHRQ Publication No.12-05164-EF-3. December 2013. http://www.uspreventiveservicestaskforce.org/uspstf12/brcatest/brcatestsumm.